Can Canopy Growth Stock Compete in the U.S.?

One of the latest debates among cannabis investors is how Canadian cannabis companies like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) will effectively compete against U.S. players like Curaleaf (TSXV:CURA).

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

There’s no doubt that Canopy Growth (TSX:WEED)(NYSE:CGC) is one of the best stocks in the cannabis sector. Investors are more excited than ever about Federal U.S. cannabis legalization, buoying all stocks in this sector in recent months. Canopy Growth stock is no exception.

However, some of its peers, namely Curaleaf Holdings (TSXV:CURA), are ahead of the curve in this regard. Recently, Canopy made a big move in the United States. But will that be enough to topple the other players in the market? Let’s find out.

Steps taken to gain market share in the U.S.

This Smith Falls-based company announced that it would be introducing four new cannabis-infused drinks in the United States. Its Quatreau products will contain 20 grams of CBD oil and will be sold online in four flavours. The company believes that there is ample scope for growth, as Canadians and Americans have almost identical consumer preferences. I believe that this could be a significant opportunity, as cannabis laws are overhauled by the Democrats.

Square and New Frontier Data reports suggest that $121 billion will be spent on CBD oil between 2020 and 2025 in the United States. Moreover, the predictions indicate that consumers aged between 34 and 44 years will fuel the expenses.

As per Canopy’s research, two out of three Americans who are aware of CBD oil cannot name more than one producer. I believe that the highly fragmented market will play out in its favour, as Canopy is a recognized brand with a proven formula.

A promising move, but more work to be done

Canopy has definitely taken a step forward in the right direction. However, when it comes to the U.S. THC market, Curaleaf has a significant head start. Curaleaf’s the big dog in a relatively small but booming town. This has been reflected in the sharp 400% increase in the company’s stock price since 2020 lows. Additionally, with a Democratic sweep of the House and Senate, I think federal legalization is just a matter of time. Indeed, I’m convinced that there’s a great opportunity for Curaleaf to dominate the U.S. cannabis market.

Contrary to most Canadian peers, Curaleaf has built what appears to be an efficient and sustainable vertically integrated business model. It engages in the manufacturing of value-added products, which enhances its margins across the board. Furthermore, it appears this company has a management team that’s doing all the right things to promote long-term growth. I like that.

Indeed, I think Canopy will ultimately be playing an expensive game of catch-up to peers like Curaleaf.

Bottom line on Canopy Growth stock

Canopy Growth remains a top player in the cannabis market. However, the stock’s growth rate has been sluggish compared to its peers. This might be due to a pervasive belief that U.S.-fixed companies will outperform, whereas Canada-focused companies will lag.

Accordingly, right now, my top pick in the cannabis space is Curaleaf. Canopy’s a great company, but I think Curaleaf’s growing lead is going to be very hard to overcome.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. Tom Gardner owns shares of Square. The Motley Fool owns shares of and recommends Square.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »